デルキャス・システムズ
Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | 0.07 | $29M | $5M |
| 2026 Q1 | -0.03 | $25M | $287,000 |
| 2025 Q4 | -0.05 | $21M | $8M |
| 2025 Q3 | 0.02 | $21M | $4M |
| 2025 Q2 | 0.07 | $24M | $7M |
| 2025 Q1 | 0.03 | $20M | $2M |
| 2024 Q4 |
| -0.12 |
| $15M |
| -$1M |
| 2024 Q3 | 0.07 | $11M | -$4M |